GSK ...................filling its Cancer Pipeline

GSK for the past 2 years is rapidly evolving its cancer pipeline, For the past 6 months I have observed that GSK has been part of many deal related to drug or compound screening for cancer target to their synthesis and successive clinical trials....GSK has diversified its cancer target portfolio......Yesterday GSK announced that it has signed a deal with Vernalis of UK, This deal is worth $ 200 Million in fees and milestone payment....The later will be responsible for Drug discovery and GSK will be taking care of the preclinical work. Later on if any IND’s are filed then GSK will have chance to licence this compound to anyone for clinical trials.